Vardenafil

CAT: 0804-HY-B0442-01Size: 25 mgDry Ice: NoHazardous: No
CAT#: HY-B0442-01Size: 25 mg
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4[1]. Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels[2]. Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes[1]-[6].
CAS Number
[224785-90-4]
UNSPSC
12352005
Hazard Statement
H301, H373, H410
Target
Endogenous Metabolite; Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Metabolic Disease; Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Vardenafil.html
Purity
99.81
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
CCCC1=NC(C)=C2N1N=C(C(C=C(S(=O)(N3CCN(CC)CC3)=O)C=C4)=C4OCC)NC2=O
Molecular Formula
C23H32N6O4S
Molecular Weight
488.60
Precautions
H301, H373, H410
References & Citations
[1]Ashour AE, et al. Vardenafil dihydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:515-544.|[2]Saenz de Tejada I, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001;13 (5) :282-290.|[3]Gresser U, et al. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Eur J Med Res. 2002 Oct 29. 7 (10) :435-46. |[4]Oudot A, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011 Nov. 60 (5) :1020-6. |[5]Ahmed N, et al. Hepatoprotective role of vardenafil against experimentally induced hepatitis in mice. J Biochem Mol Toxicol. 2017 Mar. 31 (3) . |[6]Bódi B, et al. Long-Term PDE-5A Inhibition Improves Myofilament Function in Left and Right Ventricular Cardiomyocytes through Partially Different Mechanisms in Diabetic Rat Hearts. Antioxidants (Basel) . 2021 Nov 6. 10 (11) :1776.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PDE1; PDE3; PDE4; PDE5; PDE6
Citation 01
ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Anim Cells Syst (Seoul) . 2019 May 16;23 (3) :155-163.|Pharmacia. 2025 Jul 3.|Life Sci. 2022 Nov 15:309:120992.

Related Products

CatalogName